Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Denice D. Tsao-Wei"'
Autor:
Jocelyn Garcia-Sayre, Yvonne G. Lin, Koji Matsuo, Denice D. Tsao-Wei, Paulette Mhawech-Fauceglia, Stan Louie, Tiange Dong, Marcia A. Ciccone, Laurie L. Brunette-Masi, Huyen Q. Pham, Annie A. Yessaian, Susan G. Groshen, Grace Facio, Marissa Aldana, Laila I. Muderspach, Agustin A. Garcia, Lynda D. Roman
Publikováno v:
Gynecologic Oncology. 173:49-57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46b1835eca85f53e696326c4f5b1fb9e
https://doi.org/10.1016/j.ygyno.2023.02.016
https://doi.org/10.1016/j.ygyno.2023.02.016
Autor:
Jacek K. Pinski, Andrew V. Schally, Debra Hawes, Juergen Engel, Yu-Chong Tai, David I. Quinn, Tanya B. Dorff, Susan Groshen, Shigang Xiong, Denice D. Tsao-Wei, Stephen V. Liu
Supplemental Table 2. Grade 1, 2, 3 and 4 adverse events including all cohorts (n=18). Toxicities defined as not related to treatment were excluded.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46832ac312dd3ded85e10f1b4d72f24a
https://doi.org/10.1158/1078-0432.22458390
https://doi.org/10.1158/1078-0432.22458390
Autor:
Jacek K. Pinski, Andrew V. Schally, Debra Hawes, Juergen Engel, Yu-Chong Tai, David I. Quinn, Tanya B. Dorff, Susan Groshen, Shigang Xiong, Denice D. Tsao-Wei, Stephen V. Liu
Supplemental Table 3. Cardiac and Pituitary Analyses. FSH, follicle stimulating hormone; MUGA, multigated acquisition study; TSH, thyroid stimulating hormone.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179b02a69d301e97cc2b73d7b267c579
https://doi.org/10.1158/1078-0432.22458387.v1
https://doi.org/10.1158/1078-0432.22458387.v1
Autor:
Jacek K. Pinski, Andrew V. Schally, Debra Hawes, Juergen Engel, Yu-Chong Tai, David I. Quinn, Tanya B. Dorff, Susan Groshen, Shigang Xiong, Denice D. Tsao-Wei, Stephen V. Liu
Supplemental Table 1. Baseline disease characteristics describing site of disease as bone, lymph node, and/or visceral involvement, with organ noted.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab09a3d0ed574294576759319a38772
https://doi.org/10.1158/1078-0432.22458393
https://doi.org/10.1158/1078-0432.22458393
Autor:
Jacek K. Pinski, Andrew V. Schally, Debra Hawes, Juergen Engel, Yu-Chong Tai, David I. Quinn, Tanya B. Dorff, Susan Groshen, Shigang Xiong, Denice D. Tsao-Wei, Stephen V. Liu
Purpose: AEZS-108, formerly AN-152, is a cytotoxic hybrid molecule consisting of a luteinizing hormone-releasing hormone (LHRH) agonist moiety covalently coupled to doxorubicin, allowing it to deliver doxorubicin selectively to cells expressing LHRH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b0a0325ec31ac2b7a37b081721209e
https://doi.org/10.1158/1078-0432.c.6523935
https://doi.org/10.1158/1078-0432.c.6523935
Autor:
David I. Quinn, Paul Frankel, Edward M. Newman, Denice D. Tsao-Wei, Gurkamal Chatta, Primo N. Lara, Susan Groshen, Stella Khoo, John Wright, Heinz-Josef Lenz, Ana Aparicio, Przemyslaw Twardowski, David R. Gandara
Publikováno v:
Investigational New Drugs. 39:812-820
Background: Until the advent of T cell check point inhibitors standard second-line therapy for patients with metastatic urothelial cancer (mUC) was undefined. Histone deacetylase inhibitors (HDACi) have anti-cancer activity in a variety of tumor mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d02b1f60cb45d27beb919e9f276c15c
https://doi.org/10.1007/s10637-020-01038-6
https://doi.org/10.1007/s10637-020-01038-6
Autor:
Syma Iqbal, Afsaneh Barzi, Dana Agafitei, Kyle G. Cologne, April Choi, Heinz-Josef Lenz, Denice D. Tsao-Wei, Anthony B. El-Khoueiry
Publikováno v:
Oncologist
Lessons Learned Neoadjuvant bevacizumab with modified FOLFOX7 without radiation failed to meet the goal of pathological complete response rate; however, the low number of recurrence and disease-free survival in this population, with predominantly sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb845f7fce3cc8304e313598d196bb22
https://doi.org/10.1634/theoncologist.2020-0642
https://doi.org/10.1634/theoncologist.2020-0642
Autor:
Yael P. Mosse, Brian Weiss, Fariba Goodarzian, Navin Pinto, Judith G. Villablanca, Gregory A. Yanik, Scarlett Czarnecki, Suzanne Shusterman, Araz Marachelian, Anasheh Shamirian, Hiroyuki Shimada, Rachel Berkovich, John M. Maris, Daphne A. Haas-Kogan, Julie R. Park, M. Meaghan Granger, Clare J. Twist, Steven G. DuBois, Lingyun Ji, Kieuhoa T. Vo, Susan L. Cohn, Katherine K. Matthay, Denice D. Tsao-Wei, Kelly C. Goldsmith, Susan Groshen, Meredith S. Irwin
Publikováno v:
J Clin Oncol
PURPOSE 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate. PATIENTS AND METHODS Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5465588083dc929da824e7729c79092
https://europepmc.org/articles/PMC8547934/
https://europepmc.org/articles/PMC8547934/
Autor:
Sarmad Sadeghi, Laurence A. Doyle, Edward M. Newman, Primo N. Lara, Rahul R. Parikh, Christopher J. Hoimes, David I. Quinn, Susan Groshen, Denice D. Tsao-Wei, Tanya B. Dorff, Amir Mortazavi, Cheryl Kefauver
Publikováno v:
Journal of Clinical Oncology. 37:2682-2688
PURPOSE Patients with metastatic urothelial carcinoma are often ineligible for cisplatin-based treatments. A National Cancer Institute Cancer Therapy Evaluation Program–sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribuli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bfd60ad7ccb67d6ca3a5177bb1df30f
https://doi.org/10.1200/jco.19.00861
https://doi.org/10.1200/jco.19.00861
Autor:
Sarmad Sadeghi, Primo N. Lara, Afsaneh Barzi, Siamak Daneshmand, David I. Quinn, Inderbir S. Gill, Denice D. Tsao-Wei, Eric A. Klein, David F. Penson, Dongyun Yang, Jacek Pinski
Publikováno v:
Cancer. 125:3853-3863
BACKGROUND Several studies have investigated the relationship between experience measured by caseload and oncological outcomes, economics, and access to care for prostate cancer care. Oncological outcomes have been limited to biochemical failure afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cce16650569f7684ada01da9f6c9846
https://doi.org/10.1002/cncr.32290
https://doi.org/10.1002/cncr.32290